comparemela.com

Latest Breaking News On - Second vaccine - Page 11 : comparemela.com

China: Erster Todestag von Corona-„Whistleblower

China: Erster Todestag von Corona-„Whistleblower
berliner-zeitung.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from berliner-zeitung.de Daily Mail and Mail on Sunday newspapers.

Perlu Dua Kali, Ini Fungsi Suntikan Pertama dan Kedua Vaksin Covid-19

Perlu Dua Kali, Ini Fungsi Suntikan Pertama dan Kedua Vaksin Covid-19
tribunnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tribunnews.com Daily Mail and Mail on Sunday newspapers.

Corona-Impfung: Lieferengpass bremst Impfkampagne: Der Bund versprach dem Kanton Thurgau 3000 Impfdosen mehr als bisher geliefert wurden

Corona-Impfung: Lieferengpass bremst Impfkampagne: Der Bund versprach dem Kanton Thurgau 3000 Impfdosen mehr als bisher geliefert wurden
tagblatt.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tagblatt.ch Daily Mail and Mail on Sunday newspapers.

Russia s Second Vaccine EpiVacCorona 100 Per Cent Effective In Early-Stage Trials: Report

Russia began testing EpiVacCorona in November. (Representational) Moscow, Russia: A candidate COVID-19 vaccine known as EpiVacCorona, Russia s second to be registered, proved 100% effective in early-stage trials, Russian consumer health watchdog Rospotrebnadzor has told local media. The data, based on Phase I and II trials, were released before the start of a larger Phase III trial which would normally involve thousands of participants and a placebo group as a comparison. The effectiveness of the vaccine is made up of its immunological effectiveness and preventative effectiveness, the TASS news agency reported, citing Rospotrebnadzor. According to results of the first and second phases of clinical trials, the immunological effectiveness of the EpiVacCorona vaccine is 100%.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.